[1]傅晓莹 郭文龙 关海霞.肢端肥大症的死亡风险及影响因素[J].国际内分泌代谢杂志,2022,42(04):264-267.[doi:10.3760/cma.j.cn121383-20210610-06021]
　Fu Xiaoying,Guo Wenlong,Guan Haixia..Mortality in acromegaly[J].International Journal of Endocrinology and Metabolism,2022,42(04):264-267.[doi:10.3760/cma.j.cn121383-20210610-06021]
点击复制

肢端肥大症的死亡风险及影响因素()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年04期
页码:
264-267
栏目:
临床研究
出版日期:
2022-07-20

文章信息/Info

Title:
Mortality in acromegaly
作者:
傅晓莹1 郭文龙2 关海霞1
1广东省人民医院,广东省医学科学院内分泌科,广州 510080; 2广东省人民医院,广东省医学科学院神经外科,广州 510080
Author(s):
Fu Xiaoying1;  Guo Wenlong2;  Guan Haixia1.
1Department of Endocrinology, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, China; 2Department of Neurosurgery, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510080, China
关键词:
肢端肥大症;  死亡率;  治疗
Keywords:
Acromegaly;  Mortality;  Treatment
DOI:
10.3760/cma.j.cn121383-20210610-06021
摘要:
肢端肥大症(acromegaly)是一种起病隐匿的慢性进展性内分泌代谢性疾病,可引起多系统并发症。肢端肥大症患者的死亡风险较一般人群增加2～3倍,既往传统的手术治疗并不能使死亡风险回归正常,术后仍有40%～50%的患者血清生长激素水平未缓解,这和患者死亡率增加密切相关。随着治疗药物的增多,已证明长效生长抑素受体配体(somatostatin receptor ligands,SRLs)、生长激素受体拮抗剂(GH receptor antagonist,GHRA)等药物可有效控制患者生长激素水平,进一步降低患者的死亡风险。本文对肢端肥大症患者的死亡风险及不同治疗方式对死亡风险的影响进行综述。
Abstract:
Acromegaly is a chronic disorder characterized by growth hormone(GH)hypersecretion, which could cause multiple systemic complications. Patients with acromegaly are associated with an increased risk of death in the general population. Traditional surgical treatment does not normalize the risk of death, and serum GH levels remain unrelieved in about 40%-50% patients after surgery, which is closely related to the increased mortality. As the increase of therapeutic drugs, somatostatin receptor ligands(SRLs), GH receptor antagonist(GHRA)and other drugs have been proved to be effective in controlling the level of GH in patients,and further reduce the risk of death. This review focuses on treatment and mortality in acromegaly.

参考文献/References:

[1] Wright AD,Hill DM,Lowy C,et al.Mortality in acromegaly[J].Q J Med,1970,39(153):1-16.
[2] Dekkers OM,Biermasz NR,Pereira AM,et al.Mortality in acromegaly:a metaanalysis[J].J Clin Endocrinol Metab,2008,93(1):61-67.DOI:10.1210/jc.2007-1191.
[3] Holdaway IM,Bolland MJ,Gamble GD.A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly[J].Eur J Endocrinol,2008,159(2):89-95.DOI:10.1530/EJE-08-0267.
[4] Bolfi F,Neves AF,Boguszewski CL,et al.Mortality in acromegaly decreased in the last decade:a systematic review and meta-analysis[J].Eur J Endocrinol,2018,179(1):59-71.DOI:10.1530/EJE-18-0255.
[5] Arosio M,Reimondo G,Malchiodi E,et al.Predictors of morbidity and mortality in acromegaly:an Italian survey[J].Eur J Endocrinol,2012,167(2):189-198.DOI:10.1530/eje-12-0084.
[6] Dal J,Leisner MZ,Hermansen K,et al.Cancer incidence in patients with acromegaly:a cohort study and meta-analysis of the literature[J].J Clin Endocrinol Metab,2018,103(6):2182-2188.DOI:10.1210/jc.2017-02457.
[7] Terzolo M,Reimondo G,Berchialla P,et al.Acromegaly is associated with increased cancer risk:a survey in Italy[J].Endocr Relat Cancer,2017,24(9):495-504.DOI:10.1530/erc-16-0553.
[8] Wu JC,Huang WC,Chang HK,et al.Natural history of acromegaly:incidences,re-operations,cancers,and mortality rates in a national cohort[J].Neuroendocrinology,2020,110(11-12):977-987.DOI:10.1159/000505332.
[9] Colao A,Ferone D,Marzullo P,et al.Systemic complications of acromegaly:epidemiology,pathogenesis,and management[J].Endocr Rev,2004,25(1):102-152.DOI:10.1210/er.2002-0022.
[10] Ritvonen E,Löyttyniemi E,Jaatinen P,et al.Mortality in acromegaly:a 20-year follow-up study[J].Endocr Relat Cancer,2016,23(6):469-480.DOI:10.1530/erc-16-0106.
[11] Sherlock M,Reulen RC,Alonso AA,et al.ACTH deficiency,higher doses of hydrocortisone replacement,and radiotherapy are independent predictors of mortality in patients with acromegaly[J].J Clin Endocrinol Metab,2009,94(11):4216-4223.DOI:10.1210/jc.2009-1097.
[12] Mercado M,Gonzalez B,Vargas G,et al.Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic[J].J Clin Endocrinol Metab,2014,99(12):4438-4446.DOI:10.1210/jc.2014-2670.
[13] Esposito D,Ragnarsson O,Granfeldt D,et al.Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study[J].Eur J Endocrinol,2018,178(5):459-469.DOI:10.1530/eje-18-0015.
[14] Bogazzi F,Colao A,Rossi G,et al.Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly:a retrospective cohort study[J].Eur J Endocrinol,2013,169(3):367-376.DOI:10.1530/EJE-13-0166.
[15] Maione L,Brue T,Beckers A,et al.Changes in the management and comorbidities of acromegaly over three decades:the French Acromegaly Registry[J].Eur J Endocrinol,2017,176(5):645-655.DOI:10.1530/EJE-16-1064.
[16] Colao A,Vandeva S,Pivonello R,et al.Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania(Italy)[J].Eur J Endocrinol,2014,171(2):263-273.DOI:10.1530/EJE-13-1022.
[17] Tritos NA,Mattsson AF,Vila G,et al.All-cause mortality in patients with acromegaly treated with pegvisomant:an ACROSTUDY analysis[J].Eur J Endocrinol,2020,182(3):285-292.DOI:10.1530/eje-19-0794.
[18] Kasuki L,Machado EO,Ogino LL,et al.Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center:efficacy,safety and predictors of response[J].Arch Endocrinol Metab,2016,60(5):479-485.DOI:10.1590/2359-3997000000210.
[19] Tritos NA,Chanson P,Jimenez C,et al.Effectiveness of first-line pegvisomant monotherapy in acromegaly:an ACROSTUDY analysis[J].Eur J Endocrinol,2017,176(2):213-220.DOI:10.1530/EJE-16-0697.
[20] Kasuki L,Rocha PDS,Lamback EB,et al.Determinants of morbidities and mortality in acromegaly[J].Arch Endocrinol Metab,2019,63(6):630-637.DOI:10.20945/2359-3997000000193.
[21] Ayuk J,Clayton RN,Holder G,et al.Growth hormone and pituitary radiotherapy,but not serum insulin-like growth factor-I concentrations,predict excess mortality in patients with acromegaly[J].J Clin Endocrinol Metab,2004,89(4):1613-1617.DOI:10.1210/jc.2003-031584.
[22] O'Reilly MW,Reulen RC,Gupta S,et al.ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma:long-term follow-up of 519 patients in two large European centres[J].Clin Endocrinol(Oxf),2016,85(5):748-756.DOI:10.1111/cen.13141.

相似文献/References:

[1]刘洪宇,李征,郭莹,等.肢端肥大症患者治疗前后心脏结构和功能的变化[J].国际内分泌代谢杂志,2021,41(04):318.[doi:10.3760/cma.j.cn121383-20200723-07060]
　Liu Hongyu,Li Zheng,Guo Ying,et al.Changes of cardiac structure and function in patients with acromegaly before and after treatment[J].International Journal of Endocrinology and Metabolism,2021,41(04):318.[doi:10.3760/cma.j.cn121383-20200723-07060]

备注/Memo

备注/Memo:
通信作者:关海霞,Email: hxguan@vip.126.com
更新日期/Last Update: 2022-06-20